Clinical trial

Selumetinib and Olaparib in Solid Tumors

NCT03162627

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2017-08-04

PhasePHASE1

Study timeline

Study start (actual)2017-08-04Date precision: day

Registry last updated2026-04-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Malignant Neoplasm of Breastunresolved

Malignant Neoplasms of Digestive Organsunresolved

Malignant Neoplasms of Female Genital Organsunresolved

Malignant Neoplasms of Male Genital Organsunresolved

Malignant Neoplasms of Thyroid and Other Endocrine Glandsunresolved

Interventions

SelumetinibDRUG · verified · RxNorm: selumetinib

OlaparibDRUG · verified · RxNorm: olaparib

Sponsors & collaborators

M.D. Anderson Cancer Centerlead sponsor

AstraZenecacollaborator

Mapped research locations

HoustonTexas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03162627 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.